ZyVersa Therapeutics Current Cash

ZyVersa Therapeutics's current cash stands at $300M as of March 2026. That compares with $1.6B in the prior-year period — down 81.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ZyVersa Therapeutics reported $300M in current cash versus $1.6B a year earlier — a 81.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.6B in the prior-year period — down 81.2% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ZyVersa Therapeutics's current cash evolved across reporting periods, while the comparison chart places ZVSA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.